All Activity

I was very pleased to find this site.I wanted to thank you for this great read!! I definitely enjoying every little bit of it and I have you bookmarked to check out new stuff you post 朱古力瘤宜及早用藥 避免多次手術影響生育

This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free. 香港波鞋店推介2025｜盡覽7間旺角、銅鑼灣信譽良好波鞋舖 絕版Nike、adidas、New Balance任君選擇

CBD is widely used for personal wellness. In the not-so-distant future, it could be used for environmental wellness. By Phillip Smith, The American Hemp Monitor Many ubiquitous plastics we use for everything from water bottles to food packaging to substrates for flexible electronics are made from petroleum-based materials such as polyethylene terephthalate (PET), which not only consume large quantities of fossil fuels but also break down into tiny particles called “microplastics.” These particles leach chemicals, including PET, into our air, water and food, and are linked to inflammation and cell damage. Hemp, or more precisely, the hemp-derived cannabinoid CBD, may offer a viable alternative. In a study recently published in the journal Chem Circularity, a team of scientists and engineers demonstrated a hemp-derived thermoplastic that can stretch up to 16 times its original length. The material has a high “glass transition temperature,” a quality that allows plastics to stay dry and durable when they encounter boiling hot water. Scientists have been looking for green alternatives to PET, but most plant-based polymers cannot match hemp’s glass transition temperature and cost more to produce. Additionally, producing bio-based plastics typically requires high-temperature catalysts, making large-scale production impractical due to challenges with catalyst removal and final product purification. “Very few, if any, plastics made from natural resources have this quality,” said Gregory Sotzing, study author and UConn Department of Chemistry professor. “Current-day polycarbonate is made from bisphenol-A, a known endocrine disruptor. The hope here is that cannabidiol (CBD) can take the place of bisphenol-A found in today’s processed plastics,” he added. “Our work has established CBD-based polycarbonates as sustainable replacements for widely used thermoplastics such as PET,” said co-author Mukerrem Cakmak of Purdue University. “We have developed a rigorous processing science framework that links molecular architecture to melt processability, orientation development, and stretchability without compromising manufacturability.” To compete with PETs, substitutes require medium- to high-temperature stability and melt processability, or the ability to easily melt, deform and shape a material, which the team has achieved in a hemp-based polycarbonate for the first time. They did so by testing processing parameters that yield the right structure and properties for widespread use, and by establishing guidelines for the material’s industrial processing. “This polycarbonate has, as a smooth film, a very high contact angle with water. We were not expecting our polyCBD-carbonate to have a higher contact angle than most polyolefins,” said Sotzing, noting that materials with this property can be used as nanoparticles for drug delivery and for catheter coatings. And they can be recycled. “We can chemically recycle it with a base where the polyesters can be depolymerized using a base to break it down to the starting materials. We don’t need enzymes,” said Sotzing. “What happens is it will hydrolyze or break apart the polymer chain, and the CBD can be recovered.” There is not currently enough CBD being produced globally to fully replace PET for plastics, but that means only that more hemp would need to be grown to supply demand once it emerges. That would be just one more application for this tremendously versatile plant that already supplies oils, fibers, seeds and cannabinoids, intoxicating and otherwise. “We came together on this project to try to replace conventional petroleum-based plastics with something found in nature. We are finding new ways to use the entire plant. That’s what was done with oil, in that they found a way to use every little drop, even down to the sludge that becomes asphalt,” said Sotzing. “Now, we are doing that with hemp, too. There are plenty of things inside that plant that are useful.” This story was first published by The American Hemp Monitor. The post Hemp-Based Plastic Shows Promise As Environmentally Friendly Alternative To Traditional Packaging Materials, Study Finds appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for taking the time to discuss this, I feel strongly about it and love learning more on this topic. hptoto alternatif

Very efficiently written information. It will be beneficial to anybody who utilizes it, including me. Keep up the good work. For sure i will check out more posts. This site seems to get a good amount of visitors. slot gacor

“Our focus was to faithfully implement the framework enacted by the general assembly.” By Adam Friedman, Tennessee Lookout A combination of state and federal rules are going to reshape Tennessee’s once-burgeoning hemp industry starting in July. Most of Tennessee’s most popular hemp-derived cannabis products, like THCA, will be illegal to sell as the Tennessee Alcoholic Beverage Commission assumes full regulatory control of hemp and begins enforcing a ban passed in 2025 by state lawmakers. The commission became the state agency responsible for hemp at the start of the year but a last-minute deal allowed companies operating under the old regulatory framework to continue selling products like THCA until June 30. Officials with the Alcoholic Beverage Commission appeared before the legislature’s government operations committee in May to finalize the rules, acknowledging that most of the public comments focused on frustrations with the THCA ban. “Our focus was to faithfully implement the framework enacted by the general assembly,” said Russell Thomas, the executive director of the commission. After Congress passed the 2018 Farm Bill, new marijuana-like products were sold in states that hadn’t already legalized it. These new, mostly smokable, drinkable and edible consumer items are derived from hemp, which allowed them to avoid Tennessee’s ban on THC products, but still produce a similar type of high. The most glaring loophole was THCA. When burned, THCA essentially turns into THC, the psychoactive ingredient in marijuana that is illegal in Tennessee. THCA, because it comes from hemp, technically has a THC content below the state’s previous legal threshold. The industry quickly grew in Tennessee, with stores popping up across the state to sell the products. But starting in 2022, state Republican lawmakers began trying to rein in the industry, in part because at one point there were no age restrictions on who could buy it. Initial outright bans proposed by lawmakers failed to pass the legislature, in part due to financial concerns. In 2022, the state’s legislative fiscal review committee estimated that hemp products had an economic impact of $180 million. But marijuana prohibitionist lawmakers eventually got their way in May 2025, passing legislation to close the THCA loophole. U.S. Congress followed suit, passing a law in November 2025 to close the THCA loophole nationally by 2026. Industry experts estimated that 75 percent of hemp sales come from THCA, and expect that once the ban fully goes into effect on July 1, it will be a death blow to the industry. Rep. John Crawford, a Kingsport Republican, said during the hearing that the new rules are likely to put a wholesaler in his district out of business. ”I have a really hard time with that we gave them permission over the last year, and now we’re taking that back,” Crawford said. The ban is also expected to impact the state’s budget, where officials have already reduced this year’s hemp wholesale tax projections from more than $55 million to less than $10 million. Hanging over the whole hemp conversation is a move by President Donald Trump’s administration to reclassify marijuana in April from Schedule I, considered a dangerous addictive drug to Schedule III, recognizing its potential medical benefits. Tennessee doesn’t have a medical marijuana program, but did have a provision in law requiring the health department to review its options if marijuana were ever reclassified. But Republican lawmakers passed a bill this year removing that provision and requiring the legislature to pass its own law creating any medical marijuana program. Proposals for a medical marijuana program in Tennessee are expected to be proposed during the next legislative session in January. This story was first published by Tennessee Lookout. The post Tennessee Will Make It Illegal To Sell THCA And Other Hemp Products Starting On July 1 Under Newly Finalized Rules appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I recently found many useful information in your website especially this blog page. Among the lots of comments on your articles. Thanks for sharing. instant lawn suppliers

This article gives the light in which we can observe the reality. This is very nice one and gives indepth information. Thanks for this nice article. kokitoto link alternatif

Thanks for the blog loaded with so many information. Stopping by your blog helped me to get what I was looking for. unik4d situs 4d

Wow i can say that this is another great article as expected of this blog.Bookmarked this site.. 香港寄英國

“I can tell you, it absolutely does help children with seizures. It does help cancer patients, because we all know them in our lives.” By Skylar Laird, South Carolina Daily Gazette Accusations of lying and not being enough of a Republican flew during an often-contentious debate among GOP candidates for attorney general Wednesday night. Sen. Stephen Goldfinch and 1st Circuit Solicitor David Pascoe frequently exchanged barbs during the hourlong debate, while 8th Circuit Solicitor David Stumbo stayed out of the fray. The candidates often agreed at least broadly on issues, though they sometimes differed on specifics. Early voting for the June 9 election to replace Attorney General Alan Wilson, who is running for governor, started Tuesday and will continue weekdays through June 5. The winner will face the only Democrat to file, Charleston attorney Richard Hricik, in November. The debate was hosted and broadcast by SCETV. The clearest dividing line came over a question about whether the candidates would support legalizing medical marijuana. The Senate has twice passed legislation allowing cannabis to be used medicinally for certain illnesses. Both bills died in the House without a floor vote—thrown out in 2022 on a technical ruling as floor debate began and in 2024 in committee as the clock ran out on the session. But the issue is likely to return after the federal government in April loosened restrictions on medical marijuana products in states where they’re legal and set hearings this summer for rescheduling the drug. Pascoe questioned why the federal government took so long to change the drug’s classification in the first place. “I can tell you, it absolutely does help children with seizures. It does help cancer patients, because we all know them in our lives,” Pascoe said. “So, I applaud the Department of Justice for that rescheduling.” Stumbo disagreed. The state already legalized growing hemp, which naturally lacks enough THC to get people high. There’s no reason to do anything more, he said. “I believe the medical marijuana bill now is just a Trojan horse for recreational use, and I oppose it,” Stumbo said. Goldfinch voted for the “Compassionate Care Act” in both 2022 and 2024. It would have allowed people with debilitating medical conditions to eat, vape or topically apply cannabis products under heavy regulations. But on Wednesday night, he didn’t give a yes-or-no answer on medical marijuana. First, he said, legislators need to address THC-infused drinks and gummies effectively legalized by a 2018 federal law that left a lot of gray area. “Whatever your position is, honestly, I think it’s a moot point at this point, because it is ubiquitous in South Carolina, and it’s a real problem, especially the stuff that’s unregulated,” Goldfinch said. “It needs to be regulated.” Legislation limiting sales of the intoxicating hemp products could still become law this year. A compromise between differing versions passed by the House and Senate could be worked out when legislators return next month to finish work on the state budget. But agreement on where to draw the line could be difficult. Earlier this year, a separate bill banning most hemp products got returned to committee amid a chaotic divide among Republicans on the House floor. This story was first published by South Carolina Daily Gazette. Unrelated content excised by Marijuana Moment. Photo courtesy of Mike Latimer. The post South Carolina GOP Attorney General Candidates Clash On Medical Marijuana And Hemp During Debate appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“None of us really can effectively advise our licensees, which is just incredibly frustrating, especially with a ticking clock.” By Amanda Watford, Stateline The U.S. Department of Justice’s recent decision to downgrade the drug classification for medical cannabis will help medical marijuana businesses. Companies will be able to claim some federal tax benefits. New research can start up at state universities. But the broader divide between federal and state marijuana policy remains largely intact, leaving states to navigate a fragmented and still-evolving cannabis landscape with few clear answers about what comes next. The unprecedented change in April reclassifying medical marijuana from Schedule I to Schedule III means the federal government is acknowledging an accepted healthcare use for cannabis. Recreational marijuana, however, remains a Schedule I drug under federal policy, even though 24 states and the District of Columbia allow recreational cannabis in various forms, from dried flower to vaping oils to processed gummy candies. The U.S. Drug Enforcement Administration is set to hold its first hearing at the end of June on the possible de-scheduling of marijuana broadly, which would include recreational or adult-use cannabis. Until then, some experts say little is expected to change for the more than half of states with medical or recreational marijuana programs. “This change is sort of catching up to what states are already doing,” said Katharine Neill Harris, a drug policy fellow at Rice University’s Baker Institute for Public Policy. “In some ways the federal government is following the states on this issue.” States have spent years building regulatory frameworks for medical and recreational marijuana programs—including licensing systems, tax structures, testing requirements and retail oversight. Following the DEA’s announcement in April that it would reschedule medical cannabis, some state commissions acknowledged the decision but stressed that their laws have not changed and that they are awaiting further federal guidance. In Nevada, for example, state cannabis officials released a statement noting that the rescheduling change allows medical cannabis licensees to register with the DEA, while also emphasizing that Nevada law still classifies non-medical marijuana as a Schedule I substance. In mid-May, the California Department of Cannabis Control proposed emergency regulations that would allow businesses holding licenses for both medical and recreational marijuana to obtain separate licenses. The change could position cannabis businesses to take advantage of potential benefits tied to the rescheduling of medical marijuana. Many of the day-to-day functions of state cannabis programs are expected to remain intact, according to experts. “Right now, nothing would have to change for states because we don’t know what the federal regulations are going to look like for managing medical cannabis,” said Heather Trela, the director of operations and a fellow at the Rockefeller Institute of Government, a nonpartisan public policy think tank. “Everyone’s kind of figuring it out right now, and we don’t have all the details, so it’s hard for states,” she said. State cannabis regulators and officials in several states, including Oklahoma, Vermont and Washington, told Stateline they are waiting for guidance from the DEA and other federal agencies before determining whether businesses will be required to register with the DEA, qualify for federal tax relief or face new compliance requirements, and whether states may need to revise their own cannabis laws. “None of us really can effectively advise our licensees, which is just incredibly frustrating, especially with a ticking clock,” said James Pepper, the chair of the Vermont Cannabis Control Board, which regulates the state’s medical and adult-use market. In the coming months, other federal agencies may issue guidance on how rescheduling will affect existing rules, according to policy experts. The U.S. Department of Transportation said in December that drug testing and licensing standards will not change, and TSA rules still prohibit carrying marijuana on flights. Financial guidance from the IRS and the Treasury Department also are still pending. ‘Taxed like a normal business’ But some marijuana policy experts and industry leaders say the federal shift could bring major changes to cannabis business operations and scientific research. Cannabis businesses have long been blocked from taking certain federal tax deductions because marijuana was classified as a Schedule I substance. Some industry leaders say moving medical cannabis to Schedule III could ease some of those constraints. “Going forward, we can be treated and taxed like a normal business, which ultimately helps the bottom line and allows us to reinvest more meaningfully in the states where we operate,” said Lauren Niehaus, the executive director of government relations at Trulieve Cannabis Corp., one of the largest cannabis companies in the country. Trulieve, based in Florida, operates dispensaries in eight states. The tax policy change is a central issue for cannabis operators across the board, from small businesses to large multistate companies, Niehaus said. Ryan Hunter, the chief revenue officer of Spherex Labs, said rescheduling changes could shift investor and lender attitudes toward the cannabis industry, with some capital partners becoming more willing to invest. But Hunter said the latest federal change also creates new uncertainty for companies operating in both medical and recreational markets, including Spherex Labs, which operates in Colorado. “Our business is still very much in wait-and-see mode,” Hunter said. “There are a lot of positive gains here, but really more than anything, a lot more confusion.” The federal government has effectively created different legal frameworks for the same substance, he added. Medical cannabis is now federally recognized, while recreational marijuana and its consumers remain in conflict with federal law. The rescheduling change also carries federal registration requirements under the Controlled Substances Act, a law that would require medical cannabis businesses to register with the DEA, pay annual fees, and comply with detailed reporting, inventory and security rules that may overlap or conflict with existing state systems. Spherex Labs has chosen not to register at this time, Hunter said, opting to wait for further federal guidance. Earlier this month, the Oklahoma Bureau of Narcotics and Dangerous Drugs Control sent a letter to licensed medical cannabis businesses encouraging them to register with the DEA and warning of possible sanctions, including revocation of their state licenses, for failing to comply with federal requirements. But the Oklahoma Medical Marijuana Authority, which oversees cannabis licensing and regulation in the state, told Stateline the letter came as a surprise and that it remains unclear whether federal officials actually intend to require DEA registration for medical operators. The U.S. Department of Justice recently reclassified medical marijuana from Schedule I to Schedule III, raising many questions as states across the nation wait in anticipation of the June DEA hearing. "[…] the broader divide between federal and state marijuana policy… pic.twitter.com/uARoq5wkdC — Oklahoma Medical Marijuana Authority (@OMMAOK) May 29, 2026 Other states could adopt similar federal registration requirements, according to Trela, of the Rockefeller Institute of Government. Cannabis research Some researchers and experts say rescheduling marijuana could reduce longstanding barriers to studying its medical use, safety and long-term health effects. Current research on marijuana’s effects falls short of what is needed to fully understand cannabis as a medical treatment, according to Chad Johnson, an assistant professor of pharmaceutical sciences at the University of Maryland School of Pharmacy. Johnson also is the director of the university’s medical cannabis graduate studies program. “We really do need those randomized trials to really say that cannabis is effective for treating a particular condition,” Johnson said. There are still major gaps in cannabis research, he said, including how it is formulated and delivered, such as whether methods beyond smoking, vaping or edibles may be more effective, and how to determine appropriate dosing for specific medical conditions. Johnson added that rescheduling could allow academic institutions to study products already being sold in their respective states, making research more closely aligned with what consumers are actually using, rather than relying on cannabis sourced through federally authorized suppliers. Some public health and addiction experts say the federal shift should not be interpreted as a signal that cannabis is risk-free, pointing to ongoing concerns about cannabis use disorders, dependency and effects on mental health. “It’s going to reduce the public’s perception of risk of cannabis, and right now, I don’t think the public is aware of the high potency that cannabis has,” said Dr. Alta DeRoo, the chief medical officer of the Hazelden Betty Ford Foundation, one of the largest nonprofit treatment providers for addiction and mental health. DeRoo also is a board-certified addiction medicine physician and OB-GYN. Some opponents of the change also argue it is driven as much by political and economic pressure from the cannabis industry as by evolving science. “The issue is not research. The issue is money, tax breaks for an industry, and that’s really what the whole effort to relax marijuana laws is about,” said Kevin Sabet, a former drug policy adviser to three presidential administrations and the president and CEO of Smart Approaches to Marijuana, a nonprofit that opposes legalizing marijuana. What’s next New federal changes also could face court challenges or be reversed by a future administration, according to some cannabis policy experts. Last week, the attorneys general of Indiana, Louisiana and Nebraska filed a petition for review in the U.S. Court of Appeals for the District of Columbia Circuit, arguing that the Justice Department’s rescheduling order violates federal administrative law. Louisiana and Nebraska have medical-only cannabis programs, while Indiana does not have a cannabis program at all. Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association filed a similar lawsuit earlier this month, arguing that the administration exceeded its authority under the Controlled Substances Act. At the same time, the White House’s latest National Drug Control Strategy document also raised concerns about high-potency marijuana and warned that international cartels and organized crime groups continue to exploit state cannabis legalization laws. Aside from criminal justice implications, federal restrictions have limited cannabis businesses’ access to banking, investment and long-term planning, even as state markets have expanded into a multibillion-dollar industry. Banks have largely avoided working with cannabis businesses because marijuana remains broadly illegal under federal law, which exposes financial institutions to potential regulatory penalties and compliance risks even in states where cannabis is legal. Several bills have been introduced in Congress that would provide protections for banks offering services to cannabis businesses, but no legislation has been adopted. This story was first published by Stateline. The post State Marijuana Officials Call Out ‘Frustrating’ Lack Of Federal Guidance On What Trump’s Rescheduling Move Means For Businesses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Wow, What a Excellent post. I really found this to much informatics. It is what i was searching for.I would like to suggest you that please keep sharing such type of info.Thanks hargatoto

Thanks a ton to get writing this sort of superb posting! I uncovered your web blog ideal for this demands. Contained in the grapefruit excellent plus handy discussions. Keep up to date favorable deliver the results! science of money

I wanted to thank you for this excellent read!! I definitely loved every little bit of it. I have you bookmarked your site to check out the new stuff you post. ราคาบอลวันนี้

When you play Speed Stars game, you become a top speedrunner and fight in fast races to win difficult tracks. Do you think you're very good at time, speed, accuracy, and rhythm?

Genuine Aerocity Call Girls at your service. Premium Indian and Russian escorts with luxurious experience and free home delivery anywhere in Aerocity, 24×7.

More than a quarter of the gun permit applications that Hawaii officials denied last year were due to the applicants’ status as medical marijuana patients, the state attorney general’s office says. The annual “Firearms Registration in Hawai’i” report, published last month, shows that of the 163 firearms permit applications that were rejected in 2025, 47 (28.8 percent) were denied due to medical cannabis. Medical marijuana was the leading cause of denials, ahead of mental health issues, domestic violence or other criminal offenses. Another 13 gun permit applications, or 8 percent of all rejections, were due to drug offenses. The applicants that were rejected for medical cannabis includes current as well as some former patients, as “police departments allow former patients to apply for firearm permits no less than one year after the expiration of their medical marijuana card,” the report says. Medical marijuana patient status has consistently been a leading cause of gun permit denials in Hawaii. The attorney general’s office reported, for example, that 41 percent of rejections in 2023 were due to medical cannabis. The new Hawaii data comes amid several important federal developments concerning marijuana consumers’ gun rights. The Bureau of Alcohol, Tobacco, Firearms and Explosives this month posted a proposed revised version of Form 4473, which must be filled out by anyone purchasing a gun from a federally licensed firearms dealer, to acknowledge the federally legal status of medical marijuana under the Trump administration’s recent move to reschedule the drug. Separately last month, Acting Attorney General Todd Blanche suggested that the Trump administration may soon stop aggressively defending 922(g)(3), the federal law that criminalizes gun possession by people who consume marijuana and other illegal drugs. In March, however, the Trump administration argued before the U.S. Supreme Court that the federal law barring cannabis consumers from owning guns is constitutional under the Second Amendment. And last month, Solicitor General D. John Sauer sent the justices a letter saying that the Trump administration’s move to federally reschedule marijuana should not impact their decision in that case, U.S. vs. Hemani. Meanwhile in Hawaii, legislation to legalize recreational marijuana stalled again this session. Although Hawaii senators approved a bill to legalize low-dose and low-potency marijuana, the measure didn’t advance through required steps before a key deadline. A separate marijuana legalization bill that contained provisions making the reform contingent on changes to federal law or the state Constitution, was deferred for action. Both Senate and House panels additionally deferred action on a measure to allow for the sale of certain hemp-derived cannabinoid products. Those actions came after key House lawmakers signaled that cannabis legalization proposals would not be advancing in the 2026 session, citing a lack of sufficient support in their chamber. The Hawaii Senate, however, passed a pair of resolutions calling on Congress to federally legalize marijuana, support state efforts to clear people’s conviction records and take steps to facilitate access to banking services for companies in the cannabis industry. The Senate Health and Human Services Committee also adopted separate resolutions calling on the state attorney general and health department to request an exemption from the Drug Enforcement Administration (DEA) stipulating that Hawaii is permitted to run its medical cannabis program without federal interference. A Hawaii Senate committee separately advanced legislation this year to allow patients to immediately access medical cannabis once their registrations are submitted, instead of having to wait until their cards are delivered as is the case under current law. Meanwhile, legislation to create a psychedelics task force responsible for studying and making policy recommendations on providing access to breakthrough therapies such as psilocybin and MDMA also advanced this session, but was not enacted. Legislation to allow qualifying patients to access medical marijuana at health facilities also moved ahead this year but fell short ahead of the adjournment of the session. The post More People Are Denied Gun Permits Over Medical Marijuana In Hawaii Than For Any Other Reason, Attorney General’s Report Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Components of marijuana show “consistent and statistically significant anti-tumor effects” in certain types of cancer, including glioblastoma and breast cancer, according to a new scientific review that also found cannabinoids seem to “enhance chemotherapy efficacy.” The research, published in the journal Pharmaceuticals, involved a systematic meta-analysis of preclinical trial data investigating the relationship between cannabinoid therapies and multiple cancer types. Researchers at Semmelweis University and the University of Pécs said their work “provides the most comprehensive systematic synthesis to date of preclinical evidence regarding the antitumor effects of cannabinoids across a wide spectrum of cancer models.” The review determined that cannabis compounds “show promise as adjuncts in oncotherapy, particularly in glioblastoma and breast cancer, to enhance chemotherapy efficacy.” “Cannabinoids demonstrated consistent and statistically significant antitumor effects in glioblastoma and breast cancer models,” the study authors said, noting that there’s “additional supportive evidence in lung and prostate cancer.” “Glioblastoma emerged as the tumor type with the most reproducible evidence base,” the study said. “Cannabinoids show emerging potential as adjuncts in oncological treatment, with relatively consistent signals observed particularly in glioblastoma and breast cancer models.” Of the cannabinoids included in the analysis, non-intoxicating CBD “demonstrated the broadest and most favorable profile, with consistent antitumor activity and the advantage of a well-documented safety record in clinical use.” A study of animal glioblastoma models proved the most compelling, with data showing that subjects receiving cannabinoid therapy saw reduced tumor volume by an average of −980.58 mm³ compared with the control group. For the breast cancer model, cannabinoids were associated with reduced tumor volume of −402.64 mm³ on average. When combined with the chemotherapy medication doxorubicin, the average tumor volume decrease was −1295.19 mm³ compared with doxorubicin on its own. Still, the researchers stressed that “not all combinations are beneficial and that rigorous preclinical screening is required before clinical translation,” and unlike CBD, “THC produced highly variable effects” so the therapy’s benefits may not be “universal.” This represents one of the latest pieces of scientific literature examining the therapeutic potential of cannabinoids in cancer treatment. For example, another recent systemic review concluded that studies “consistently show” that the CBD is a potential “anticancer agent across different cancer types”—and that effect applies to dogs as well as humans. A similar analysis showed that CBD “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties. Scientists explored CBD’s effect on many types of cancer—including some of the most aggressive ones, such as glioblastoma, which affects the brain. They also noted it can help suppressing the growth and metastasis of other cancers, including breast, lung, colorectal, ovarian and prostate, among others. In 2025, a paper published in the journal Pharmacology & Therapeutics, assessed a range of clinical and preclinical findings that the efficacy of chemotherapy drugs can be enhanced by medical marijuana. In a sign of greater acceptance of medical applications of cannabis, President Donald Trump’s choice to serve as the next White House drug czar has called medical marijuana a “fantastic” treatment option for seriously ill patients and said she doesn’t object to legalization, even if she might not personally agree with the policy. Also last year, a study found that “patients with cancer using cannabis report significant improvements in cancer-related symptoms.” The post Marijuana Components Have ‘Consistent’ Anti-Tumor Effects In Glioblastoma And Other Cancers, Scientific Review Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Louisiana’s governor has signed a bill that threatens to send people to jail for up to one year if they smoke marijuana within 2,000 feet of a school property—including a college campus. The legislation from Rep. Gabe Firment (R) was passed by the Senate in a 23-10 vote earlier this month after having cleared the House of Representatives in a 59-34 vote last month. Gov. Jeff Landry (R), whose staff previously testified in favor of the measure at a committee hearing, quietly signed it into law last week. The new policy applies to people who violate drug laws “while smoking, vaping, or otherwise abusing such controlled dangerous substance while on any property used for school purposes by any school, within two thousand feet of any such property, or while on a school bus.” Firment previously told senators at a House committee hearing that his bill “strengthens enforcement of Louisiana drug-free school zone laws by creating a clear behavior-based offense, so that when someone is openly smoking or vaping illegal drug in the school zone, law enforcement can act and prosecutors can prove the case.” “For marijuana, the bill establishes a clear and consistent penalty—up to a year in jail and $1,000 fine, ensuring that violations in school zones result in real, enforceable consequences,” he said. Sen. Rick Edmonds (R) argued on the Senate floor ahead of this month’s final vote that the bill, HB 568, “strengthens enforcement of Louisiana drug school zone law by adding a behavior-based trigger for violations and clarifying the penalty structure.” “The bill does not change what’s legal. It gives law enforcement a practical tool [and] ensures consistent consequences in school zones,” he said. Kevin Caldwell, Southeast legislative manager for the pro-legalization Marijuana Policy Project (MPP), said the group is “disappointed to see this deeply flawed legislation become law with the signature of Gov. Jeff Landry.” “His personal lobbying efforts forced many legislators to vote for a bill they know will have profound negative life altering consequences for potentially thousands of Louisianans,” Caldwell told Marijuana Moment. “His solution to every perceived problem has been a return to incarceration. These failed policies of the past should remain in the past.” “No child in Louisiana will be any safer after this legislation goes into effect,” he said. “But historical data clearly shows who will bear the brunt of this policy. The governor and legislature are seriously out of touch with the people of Louisiana.” In 2021, then-Gov. John Bel Edwards (D) signed a bill decriminalizing marijuana by removing the threat of jail time for possessing up to 14 grams. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, a Louisiana Senate bill to let patients with terminal and irreversible conditions use medical marijuana in hospitals is also on Landry’s desk for final action. Separate legislation to create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin, ibogaine and MDMA is also being considered this session. A lawmaker recently filed a proposal that would create a new state task force to “study and develop findings and recommendations regarding the potential legalization of recreational marijuana.” Another lawmaker also introduced a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified. Rep. Candace Newell (D)—who has long championed legislation to end cannabis criminalization and filed a similar legal marijuana pilot program measure last session—is sponsoring what’s titled the “Adult-Use Cannabis Pilot Program Regulation and Enforcement Act.” Getting the bill across the finish line could prove complicated in the conservative legislature, however. Newell’s earlier version of the pilot program legislation didn’t advance to enactment last year, and lawmakers that session also rejected other marijuana reform proposals such as one that would have established a tax system to prepare the eventual legalization of adult-use cannabis. The post Louisiana Governor Signs Bill That Will Send People To Jail For Smoking Marijuana Near College Campuses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I originally signed up just to casually explore the game selection and expected to lose interest fairly quickly like I usually do with casino sites. Somewhere during my first week using bof casino though, I realized how much more polished and enjoyable the entire experience felt compared to many alternatives online. The site stays responsive, navigation feels smooth across devices, and even longer sessions never become mentally tiring because the layout remains clean and intuitive throughout. I mostly use it during quiet evenings or short daytime breaks, and everything has remained consistently reliable so far. Deposits happen instantly, withdrawals have worked without complications, and overall the platform feels dependable enough that it has become part of my normal routine.

Three Republican members of Congress have filed separate amendments to large-scale agriculture legislation that would prevent a scheduled federal ban on hemp THC products from taking effect in November. One proposal, from Rep. Andy Barr (R-KY), would keep many hemp products legal that are currently set to be recriminalized this year, add labeling requirements and institute new taxes on sales, among other regulatory reforms. Another amendment, from Rep. Russell Fry (R-SC), would simply delay the planned recriminalization of hemp THC products for an additional two years. A third measure, from Rep. James Comer (R-KY), seeks to prevent federal officials from spending any funds to enforce sections of last year’s annual agriculture appropriations bill that significantly narrowed the scope of what constitutes federally legal hemp. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, Trump signed new spending legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. Barr’s 25-page amendment, titled the Lawful Hemp Protection Act, would change the definition of legal hemp again to allow concentrations of up to 1 percent delta-9 THC on a dry-weight basis, “measured on the finished consumer product and not on raw, floral material or any work-in-process material, including an unfinished hemp ingredient.” Cannabinoids that are not capable of being naturally produced by a cannabis plant or that are synthesized or manufactured from any starting material other than hemp would not be part of the revised definition of a legal hemp product. “Many Americans, including veterans and seniors, rely on consumer hemp products for wellness,” the legislation’s findings section says. “Ensuring that such products are consistently manufactured, accurately labeled, and domestically sourced is essential to maintaining public trust and protecting consumers. Clear provenance standards and the elimination of deceptive or look-alike products promote responsible industry growth, protect consumers, and reinforce confidence in lawful hemp commerce.” “Protecting minors and preventing children’s access to hemp products is central to the public interest and to the long-term credibility of the hemp industry. Strong age-control measures are necessary to prevent misuse and safeguard public health. Within 18 months of the proposal’s enactment, the secretary of health and human services would “establish for each cannabinoid present in a hemp-derived consumable product a maximum allowable amount of such cannabinoid per serving of such product.” Those limits would need to be updated at least once every five years or “as soon as scientific evidence warrants reconsideration.” The legislation also sets out labeling requirements for hemp-derived consumer products, including displaying per-serving and per-package THC content, as well as a statement specifying that they are only for people over the age of 21. Consumable hemp products would also need to include this text: “GOVERNMENT WARNING: (1) According to the Surgeon General, women should not consume hemp products during pregnancy because of the risk of birth defects. (2) Consumption of hemp products impairs your ability to drive a car or operate machinery and may cause health problems.” The labeling and maximum cannabinoid content provisions would only apply to “products introduced or delivered for introduction into interstate commerce on or after the date that is 180 days after the date of enactment of this Act.” Sales of hemp-derived consumable products would be subject an “in-person or virtual” age verification requirement to ensure customers are 21 or older, with a civil penalty of up $1,000 per violation and the threat of permit or registration revocation for “repeated or willful violations.” For most consumable hemp products sold in interstate commerce, excluding beverages, there would be a user fee of 5 percent of the retail sale price. It would be collected by retailers at the point of sale and remitted quarterly to the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau (TTB), with revenue earmarked to support hemp regulation and enforcement, consumer protection activities and assistance for state agencies. With respect to hemp drinks, there would be a federal tax of 5 cents per milligram of THC in each beverage, with the tax determined as of the time of removal for consumption or sale from the premises of the producer. One percent of the revenue from hemp beverages would go to the Highway Trust Fund to support state-level enforcement, training and testing technologies related to standards on zero-tolerance for impaired driving. Within a year of the the law’s enactment, TTB would establish a three-tier system for hemp-derived beverages sold in interstate commerce, modeled on the current distribution framework for alcohol. The first tier would include manufacturers, the second tier would be for distributors and wholesalers and the third tier would cover retailers. No entity could hold a permit or registration in more than one tier at a time, nor a “direct or indirect interest” in permittees or registrants in more than one tier—a separation the legislation says will be “strictly maintained.” Within 180 days of enactment, TTB would need to establish a mandatory retailer registration and licensing system for all people engaged in the sale of hemp-derived beverages in interstate commerce, and covered retailers would need to register within 30 days of the system’s launch. Hemp products would be considered “adulterated” if they exceed the maximum allowable cannabinoid content established by the secretary of health and human services, if they don’t comply with packaging rules or if they are “not derived exclusively from hemp cultivated in the United States, processed within the United States, and finished, packaged, and labeled within the United States,” the legislation says. The proposal makes clear that states, territories and Indian tribes could enact hemp product laws that are more stringent that the federal requirements under the bill, but it also says that they cannot interfere with the “passage and delivery of a hemp-derived consumable product through the borders” of their jurisdictions. One section of the measure would require the Food and Drug Administration (FDA) to publish a list of all cannabinoids known to the agency to be capable of being naturally produced by a Cannabis sativa L. plant, as reflected in peer reviewed literature, as well as a list of all tetrahydrocannabinol class cannabinoids known to the agency to be naturally occurring in the plant, within 90 days. A hemp-derived consumable product would be defined under the Federal Food, Drug, and Cosmetic Act (FFDCA) to include ingestibles, beverages, oral tinctures, sublinguals, capsules, tablets, inhalables, topicals and transdermals—all considered to be food for the purposes of the law. The legislation also contains a provision addressing hemp products covered under Medicare: “Notwithstanding any other provision of this Act, any hemp-derived consumable product (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321), as amended by section 4(a) of this Act) that is approved, authorized, or covered under Medicare Advantage Special Supplemental Benefits for the Chronically Ill (SSBCI) or Beneficiary Engagement and Incentives (BEI) under a program administered under title XVIII of the Social Security Act (42 U.S.C. 1395 et seq.), including any model tests implemented under section 1115A of such Act (42 U.S.C. 1315a) and applied under such title XVIII, shall be administered and governed exclusively under the applicable CMS system, process, or program until such date that model tests are completed.” The Trump administration launched a Centers for Medicare & Medicaid Services (CMS) program last month to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. A federal judge last week granted the government’s motion to dismiss marijuana legalization opponents’ lawsuit challenging the initiative. Under a provision of Barr’s proposal, states would be at risk of losing out on certain federal funds if they do not address hemp-impaired driving using the “same field sobriety evaluation standards and protocols that law enforcement officers apply to determine impairment caused by lawfully prescribed pharmaceutical substances, including opioids, benzodiazepines, and other controlled medications” or subject hemp-impaired drivers to the “same penalties, fines, license suspensions, and other sanctions as apply to driving under the influence of alcohol or other impairing substances.” Barr’s measure, curiously, was filed in the form of a bill and is not drafted as an actual amendment to the agriculture appropriations legislation. Industry advocates have been eagerly anticipating a standalone bill from Barr on the issue, but it’s not clear when that will be formally introduced or why what appears to be its text was filed as an improperly formatted amendment to the agriculture measure. The House Rules Committee is expected to decide next week which, if any, of the submitted amendments to H.R. 8646, the Fiscal Year Agriculture, Rural Development, Food and Drug Administration, and Related Agency appropriations bill, can advance toward floor votes. “Members should draft their amendments to the text of H.R. 8646, which is available on the Rules Committee website,” the panel said in an announcement about the process for considering the legislation. “Members should attempt to draft their amendments with actual legislative language to ensure the Committee is able to properly review and assess amendment submissions. Members should not submit amendment ‘placeholder text,’ blank attachments, or legislative text which is not consistent with the intent of the amendment,” it said. “Amendments which do not comply with this directive will not be reviewed, even if revised.” Barr spoke at a meeting with hemp industry operators earlier this month and previewed his hemp regulation bill—saying it faces opposition from a coalition of strange bedfellows including sectors of the alcohol industry, marijuana businesses and cannabis legalization opponents. Separately, White House officials recently provided Barr’s office with feedback on hemp regulatory legislation. Last month, Vince Haley, director of the White House Domestic Policy Council and James Braid, assistant to the president for legislative affairs, sent hemp policy suggestions to the congressman’s office. “We appreciate your work to advance the policy of” an executive order Trump signed in December that included provisions seeking to protect Americans’ access to CBD products, the staffers wrote in a letter to the congressman. “We are transmitting for your consideration draft legislative text and comments to address the statutory definition of final hemp-derived cannabinoid products in order to allow Americans to benefit from access to appropriate full-spectrum CBD products while preserving the Congress’s intent to restrict the sale of products that pose serious health risks,” the White House officials said, according to a social media post containing a screenshot of the letter. “We are available for discussion and further technical assistance.” Trump himself last month pushed congressional lawmakers to take action to amend the currently scheduled hemp ban, which he suggested threatens to federally recriminalize full-spectrum CBD products. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” the president said in a Truth Social post on Thursday, the same day his administration announced it is moving forward to reschedule marijuana. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Sen. Ted Cruz (R-TX) said recently that it will be an “uphill path” to avert the scheduled federal recriminalization of hemp THC products this year. Leaders of the advocacy organization Marijuana Policy Project similarly said recently that they think it will be difficult to avert the ban on hemp THC products before November, though they left open the possibility that there could be a carve-out for beverages or some reforms to THC limits. The House of Representatives recently passed a Farm Bill with provisions aimed at aiding industrial hemp producers—but without any language to delay or alter the federal recriminalization of hemp THC products that’s scheduled to take effect in November. Barr had filed a similar hemp regulation amendment to that legislation but withdrew it ahead of a Rules Committee meeting, for unknown reasons. The Wine & Spirits Wholesalers of America (WSWA) said the House’s failure to include provisions to delay or alter the ban on hemp THC products was a “missed opportunity.” “A ban will not remove these products from the market—it will push consumers toward unregulated, online channels with no age verification, no product standards and no accountability,” Dawson Hobbs, executive vice president of government affairs for WSWA said. Meanwhile, the White House Office of Management and Budget recently held a series of meetings about a Food and Drug Administration (FDA) CBD products enforcement policy. FDA also issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. CMS separately finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans. Major retailer Target, meanwhile, recently moved to expand its sales of hemp THC drinks into more states. The post GOP Lawmakers File Amendments To Prevent Federal Recriminalization Of Hemp THC Products This Year appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Poll: Marijuana consumers back Trump actions on issue; VA legalization push in budget; ATF cannabis gun reform op-ed; Study: Marijuana & exercise Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW A group of congressional lawmakers sent a letter urging the Treasury Department and Internal Revenue Service to issue “swift and clear” tax guidance for the marijuana industry now that rescheduling is underway. The latest Marijuana Moment/NuggMD quarterly tracking poll shows that cannabis consumers’ support for the Trump administration’s actions on the issue has surged since partial rescheduling was enacted—with nearly three out of four now having a favorable view. Top Virginia lawmakers are discussing the possibility of including provisions to legalize recreational marijuana sales in budget legislation that is due by July 1 after Gov. Abigail Spanberger (D) vetoed standalone bills to enact the reform—but the governor called the idea “unbelievable.” A new study found that “participants who used cannabis were more likely to engage in light and moderate activity, while vigorous activity remained less common, suggesting differences based on activity intensity.” “These findings support the idea that cannabis may influence the subjective experience of exercise, such as enjoyment or discomfort, rather than directly enhancing physical performance.” Dan Russell and Will Hall of Jones Walker LLP argue in a new Marijuana Moment op-ed that proposed changes to a Bureau of Alcohol, Tobacco, Firearms and Explosives gun purchase form represent “a formal, federal acknowledgment that medical marijuana is no longer in the same legal category it once occupied.” “None of this immediately resolves the central absurdity of the current moment. However, we are, finally, on the path to reinstating the Second Amendment rights for medical marijuana patients.” The Missouri Division of Cannabis Regulation is preparing to hold a final lottery for marijuana microbusiness licenses after instituting new rules targeting “predatory” ownership and application practices that proliferated in prior rounds. / FEDERAL Sen. Jeff Merkley (D-OR) said he will continue to “work with both Republicans and Democrats to advance common-sense cannabis reforms.” Rep. Dan Crenshaw (R-TX) tweeted that psychedelic therapies “save veteran lives,” saying the Department of Veterans Affairs’s newly announced MDMA study is “huge news and the first milestone crossed after President Trump’s announcement last month that he’s accelerating psychedelic therapies for veterans with PTSD.” / STATES Minnesota Gov. Tim Walz (D) signed a bill revising various cannabis rules and requiring regulators to issue recommendations on launching a psilocybin therapy program. Nebraska Democratic attorney general candidate Jocelyn Brasher criticized the incumbent attorney general from filing a lawsuit seeking to block federal marijuana rescheduling. A New York senator and assemblymember discussed the benefits of their legislation to legalize medical use of psilocybin in an advocacy group’s press release. A Texas Supreme Court order allowing regulators to restrict hemp-derived delta-8 THC products took effect. The Massachusetts Cannabis Control Commission held its first meeting with new members. The Nevada Cannabis Compliance Board is transitioning to a bimonthly meeting schedule beginning in July. California regulators sent updates about various cannabis issues. / LOCAL A San Antonio, Texas firefighter claims he was wrongfully terminated over medical cannabis use. / INTERNATIONAL The French Senate passed legislation containing provisions to increase penalties for use of cannabis and other drugs. / SCIENCE & HEALTH A study found that “sublingually administered CBD demonstrated a favorable safety profile and showed promise in reducing pain-related symptoms associated with exercise-induced muscle injury.” A study found that “ceremonial use of ayahuasca within neoshamanic traditions can have positive effects on suicidality.” / ADVOCACY, OPINION & ANALYSIS The United Food and Commercial Workers International Union is supporting a letter from Democratic members of Congress calling on President Donald Trump to free federal marijuana prisoners. / BUSINESS A Vireo Growth Inc. subsidiary exercised an option to purchase a New York property from a subsidiary of Innovative Industrial Properties, Inc. SNDL Inc. said its acquisition of remaining 1CM Inc. retail locations in Ontario, Canada is not expected to proceed following a prolonged regulatory review process. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Lawmakers want cannabis tax guidance from IRS (Newsletter: May 29, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

There's not a great deal, and we suggest that. We have been engaged in this for a significant period, and we fully understand how to manage our enterprise. Escort Service in Ghaziabad understands exactly what you desire, and we know how to provide you what you seek.

The website is looking bit flashy and it catches the visitors eyes. Design is pretty simple and a good user friendly interface. Slot Online Gacor